Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $16.71

Elanco Animal Health Incorporated (NYSE:ELAN) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $16.71.

Several analysts have recently issued reports on the company. Barclays upped their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. The Goldman Sachs Group lifted their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. Morgan Stanley upped their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. Finally, Jefferies Financial Group started coverage on Elanco Animal Health in a research report on Tuesday, December 19th. They set a “buy” rating and a $17.00 price objective on the stock.

Elanco Animal Health Stock Performance

ELAN opened at $13.65 on Wednesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The stock has a market capitalization of $6.73 billion, a price-to-earnings ratio of -5.46, a PEG ratio of 1.51 and a beta of 1.29. The company has a fifty day moving average of $15.81 and a 200 day moving average of $13.64. Elanco Animal Health has a fifty-two week low of $7.88 and a fifty-two week high of $16.88.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period last year, the company earned $0.19 EPS. As a group, sell-side analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, Director R David Hoover purchased 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $16.14 per share, with a total value of $322,800.00. Following the purchase, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp bought a new position in Elanco Animal Health in the 4th quarter worth about $37,000. Groupama Asset Managment purchased a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $40,000. Captrust Financial Advisors boosted its holdings in shares of Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after purchasing an additional 977 shares during the period. Covestor Ltd grew its stake in Elanco Animal Health by 1,285.1% in the first quarter. Covestor Ltd now owns 2,978 shares of the company’s stock worth $78,000 after purchasing an additional 2,763 shares in the last quarter. Finally, Comerica Bank purchased a new position in Elanco Animal Health during the 3rd quarter worth $40,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.